Daratumumab Infusion Acceleration
Latest Information Update: 11 Sep 2019
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 14 Aug 2019 Status changed from active, no longer recruiting to completed.
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2017 Planned primary completion date changed from 1 May 2017 to 31 May 2019.